↓ Direkt till sidans innehåll
↓ Direkt till sidans sekundära innehåll (sidomenyn)

Träfflista för sökning "WFRF:(Foà Robin) srt2:(2015-2019)"

Sökning: WFRF:(Foà Robin) > (2015-2019)

Resultat 1-4 av 4

Sortera/gruppera träfflistan

Sortering: Träffar per sida:

Numrering	Referens	Omslagsbild	Hitta
1.	Engert, Andreas, et al. (författare) The European Hematology Association Roadmap for European Hematology Research : a consensus document 2016 Ingår i: Haematologica. - Pavia, Italy : Ferrata Storti Foundation (Haematologica). - 0390-6078 .- 1592-8721. ; 101:2, s. 115-208 Tidskriftsartikel (refereegranskat)abstract The European Hematology Association (EHA) Roadmap for European Hematology Research highlights major achievements in diagnosis and treatment of blood disorders and identifies the greatest unmet clinical and scientific needs in those areas to enable better funded, more focused European hematology research. Initiated by the EHA, around 300 experts contributed to the consensus document, which will help European policy makers, research funders, research organizations, researchers, and patient groups make better informed decisions on hematology research. It also aims to raise public awareness of the burden of blood disorders on European society, which purely in economic terms is estimated at (sic)23 billion per year, a level of cost that is not matched in current European hematology research funding. In recent decades, hematology research has improved our fundamental understanding of the biology of blood disorders, and has improved diagnostics and treatments, sometimes in revolutionary ways. This progress highlights the potential of focused basic research programs such as this EHA Roadmap. The EHA Roadmap identifies nine 'sections' in hematology: normal hematopoiesis, malignant lymphoid and myeloid diseases, anemias and related diseases, platelet disorders, blood coagulation and hemostatic disorders, transfusion medicine, infections in hematology, and hematopoietic stem cell transplantation. These sections span 60 smaller groups of diseases or disorders. The EHA Roadmap identifies priorities and needs across the field of hematology, including those to develop targeted therapies based on genomic profiling and chemical biology, to eradicate minimal residual malignant disease, and to develop cellular immunotherapies, combination treatments, gene therapies, hematopoietic stem cell treatments, and treatments that are better tolerated by elderly patients.
2.	Giebel, Sebastian, et al. (författare) Hematopoietic stem cell transplantation for adults with Philadelphia chromosome-negative acute lymphoblastic leukemia in first remission : a position statement of the European Working Group for Adult Acute Lymphoblastic Leukemia (EWALL) and the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT) 2019 Ingår i: Bone Marrow Transplantation. - : Springer Science and Business Media LLC. - 0268-3369 .- 1476-5365. ; 54:6, s. 798-809 Forskningsöversikt (refereegranskat)abstract Allogeneic hematopoietic stem cell transplantation (HSCT) in first complete remission is a standard of care for adult patients with Philadelphia chromosome (Ph)-negative acute lymphoblastic leukemia (ALL) and high risk of relapse. However, the stratification systems vary among study groups. Inadequate response at the level of minimal residual disease is the most commonly accepted factor indicating the need for alloHSCT. In this consensus paper on behalf of the European Working Group for Adult Acute Lymphoblastic Leukemia and the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation, we summarize available evidence and reflect current clinical practice in major European study groups regarding both indications for HSCT and particular aspects of the procedure including the choice of donor, source of stem cells and conditioning. Finally, we propose recommendations for daily clinical practice as well as for planning of prospective trials.
3.	Martner, Anna, 1979, et al. (författare) NK cell expression of natural cytotoxicity receptors may determine relapse risk in older AML patients undergoing immunotherapy for remission maintenance. 2015 Ingår i: Oncotarget. - : Impact Journals, LLC. - 1949-2553. ; 6:40, s. 42569-74 Tidskriftsartikel (refereegranskat)abstract In a phase IV trial, eighty-four patients (age 18-79) with acute myeloid leukemia (AML) in first complete remission (CR) received cycles of immunotherapy with histamine dihydrochloride (HDC) and low-dose human recombinant interleukin-2 (IL-2) to prevent relapse in the post-consolidation phase. Aspects of natural killer (NK) cell biology were analyzed before and during immunotherapy with focus on outcome in older patients. In younger (<60 years old, n = 37) and older patients (>60 years old, n = 47), treatment with HDC/IL-2 resulted in an expansion of CD56bright and CD16+ NK cells in blood along with an increased NK cell expression of the natural cytotoxicity receptors (NCR) NKp30 and NKp46. In older patients, a high expression of NKp30 or NKp46 on CD16+ NK cells before and during therapy predicted leukemia-free and overall survival. These results suggest that NK cell functions determine relapse risk and survival in older AML patients and point to biomarkers of efficacy in protocols for remission maintenance.
4.	Martner, Anna, et al. (författare) Role of natural killer cell subsets and natural cytotoxicity receptors for the outcome of immunotherapy in acute myeloid leukemia. 2015 Ingår i: OncoImmunology. - 2162-4011. ; 5:1, s. 1041701-1041701 Tidskriftsartikel (refereegranskat)abstract In a phase IV trial, 84 patients (age 18-79) with acute myeloid leukemia (AML) in first complete remission (CR) received cycles of immunotherapy with histamine dihydrochloride (HDC) and low-dose human recombinant interleukin 2 (IL-2) for 18 months to prevent leukemic relapse. During cycles, the treatment resulted in expansion of CD56(bright) (CD3(-)/16(-)/56(bright)) and CD16(+) (CD3(-)/16(+)/56(+)) natural killer (NK) cells in the blood along with increased NK cell expression of the natural cytotoxicity receptors (NCRs) NKp30 and NKp46. Multivariate analyses correcting for age and risk group demonstrated that high CD56(bright) NK cell counts and high expression of NKp30 or NKp46 on CD16(+) NK cells independently predicted leukemia-free survival (LFS) and overall survival (OS). Our results suggest that the dynamics of NK cell subsets and their NCR expression may determine the efficiency of relapse-preventive immunotherapy in AML.

Skapa referenser, mejla, bekava och länka

Länka till träfflistan

Resultat 1-4 av 4

Avgränsa träffmängd

Typ av publikation: tidskriftsartikel (3); forskningsöversikt (1)

Typ av innehåll: refereegranskat (4)

Författare/redaktör: Campo, Elias (1); Fitzgibbon, Jude (1); Graf, Thomas (1); Macintyre, Elizabeth (1); Ljungman, Per (1); Cant, Andrew (1); visa fler...; Hellstrand, Kristoff ... (1); Davi, Frederic (1); Stamatopoulos, Kosta ... (1); Zolla, Lello (1); Brune, Mats, 1950 (1); Goldschmidt, Hartmut (1); Aurelius, Johan, 198 ... (1); Martner, Anna, 1979 (1); Bergh Thorén, Fredri ... (1); Flygare, Johan (1); Medvinsky, Alexander (1); Kadir, Rezan (1); Mohty, Mohamad (1); Russo, Roberta (1); Harrison, Claire (1); Griesshammer, Martin (1); Olsson, Martin (1); Stegmayr, Bernd (1); Dombret, Herve (1); Lenz, Georg (1); Delwel, Ruud (1); Anderson, Harald (1); Socié, Gérard (1); Hermine, Olivier (1); Radford, John (1); Ribrag, Vincent (1); Marks, David I. (1); Girelli, Domenico (1); Oldenburg, Johannes (1); Riise, Rebecca E, 19 ... (1); Avet-Loiseau, Herve (1); Palumbo, Antonio (1); Lopriore, Enrico (1); Buske, Christian (1); Cervantes, Francisco (1); Guilhot, François (1); Hochhaus, Andreas (1); Nagler, Arnon (1); Greinacher, Andreas (1); Bakchoul, Tamam (1); Balduini, Carlo (1); Gresele, Paolo (1); Scully, Marie (1); Coppo, Paul (1); visa färre...

Lärosäte: Lunds universitet (2); Göteborgs universitet (1); Umeå universitet (1); Uppsala universitet (1); Linköpings universitet (1); Karolinska Institutet (1)

Språk: Engelska (4)

Forskningsämne (UKÄ/SCB): Medicin och hälsovetenskap (4)

År

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

Copyright © LIBRIS - Nationella bibliotekssystem
LIBRIS.kb.se

pil uppåt

Stäng

Kopiera och spara länken för att återkomma till aktuell vy